Mercer Global Advisors
KYNB

Mercer Global Advisors’s Kyntra Bio KYNB Stock Holding History

Mercer Global Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-419
Closed -$25K – 1982
2024
Q1 		$25K Buy
+419
New +$18.1K ﹤0.01% 1912

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Mercer Global Advisors's KYNB Position: Q2 2024 in Review

Mercer Global Advisors sold out of Kyntra Bio (KYNB) in Q2 2024, closing a stake of 419 shares — an estimated $25K sold.

Mercer Global Advisors first reported a position in KYNB in Q1 2024 and held it in 1 quarter. The position peaked at $25K in Q1 2024. 102 funds tracked by Wall St. Rank hold KYNB as of Q2 2024.

  • Mercer Global Advisors reported no remaining Kyntra Bio position as of Q2 2024 after selling out during the quarter.
  • Mercer Global Advisors sold 419 Kyntra Bio shares in Q2 2024, an estimated $25K.
  • Mercer Global Advisors first reported a position in Kyntra Bio in Q1 2024 and held it in 1 quarter.
  • Mercer Global Advisors's Kyntra Bio position peaked at $25K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2024.

Based on Mercer Global Advisors's 13F filing for Q2 2024, filed 12 Aug 2024.